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Royal Infirmary, Glasgow, UKAbstractBloodstream infections caused by Candida species remain a significant cause of morbidity and mortality in hospitalized patients. Biofilm formation
by Candida species is an important virulence factor for disease pathogenesis. A prospective analysis of patients with Candida bloodstream infection
(n = 217) in Scotland (2012–2013) was performed to assess the risk factors associated with patient mortality, in particular the impact of biofilm
formation. Candida bloodstream isolates (n = 280) and clinical records for 157 patients were collected through 11 different health boards across
Scotland. Biofilm formation by clinical isolates was assessed in vitro with standard biomass assays. The role of biofilm phenotype on treatment
efficacy was also evaluated in vitro by treating preformed biofilms with fixed concentrations of different classes of antifungal. Available
mortality data for 134 patients showed that the 30-day candidaemia case mortality rate was 41%, with predisposing factors including patient
age and catheter removal. Multivariate Cox regression survival analysis for 42 patients showed a significantly higher mortality rate for Candida
albicans infection than for Candida glabrata infection. Biofilm-forming ability was significantly associated with C. albicans mortality (34 patients).
Finally, in vitro antifungal sensitivity testing showed that low biofilm formers and high biofilm formers were differentially affected by azoles and
echinocandins, but not by polyenes. This study provides further evidence that the biofilm phenotype represents a significant clinical entity,
and that isolates with this phenotype differentially respond to antifungal therapy in vitro. Collectively, these findings show that greater clinical
understanding is required with respect to Candida biofilm infections, and the implications of isolate heterogeneity.
Clinical Microbiology and Infection © 2015 The Authors. Published by Elsevier Ltd on behalf of European Society of Clinical Microbiology and
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E-mail: gordon.ramage@glasgow.ac.ukIntroductionCandida species bloodstream infection (BSI) remains a signifi-
cant cause of morbidity and mortality [1,2]. In the USA,
Candida species are ranked as the fourth most commonClinical Microbiology and Infection © 2015 The Authors. Published by El
This is an oorganisms responsible for all BSIs, and the third most common
within the intensive-care unit [2], a clinical environment that is
highly dependent on intravascular lines. Candida BSI is often
associated with the ability of Candida to form biofilms on
indwelling medical devices, such as central venous catheters
(CVCs) and prostheses [3,4]. Candida albicans remains one of
the most important candidal pathogens in this context, owing
in part to its greater capacity to form biofilms [5], and this has
profound consequences for the clinical outcome of BSI.
Therefore, removal of catheters is advocated to improve sur-
vival rates, on the basis of meta-analysis evidence from current
guidelines [6,7].Clin Microbiol Infect 2016; 22: 87–93
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attempt to analyse the risk factors associated with patients with
Candida BSI. Biofilm formation has been reported as an inde-
pendent predictor of mortality, in addition to inadequate anti-
fungal therapy and APACHE III scores [8]. Analysis of the
association of mortality with biofilm-forming ability demon-
strated that both C. albicans and Candida parapsilosis were asso-
ciated with increased mortality. A subsequent prospective
case–control study showed that Candida BSI biofilm-forming
isolates could be independently predicted by the presence of
CVCs, urinary catheters, total parenteral nutrition, and diabetes
mellitus [9]. Moreover, the hospital length of stay and cost of
antifungal therapy were also greater in those with biofilm-
forming isolates, and these patients had a greater risk of hospi-
tal mortality (OR 1.77). However, these studies used binary
categorization of biofilm formation, i.e. biofilm formers or non-
formers, on the basis of in vitro bioassays. Our group has recently
reported that biofilm formation by C. albicans is heterogeneous,
and that, rather than biofilm formation being a binary function, it
can be considered on a spectrum or within defined categories
[10]. Therefore, there remains a gap in our knowledge as to
whether patients with isolates defined as low biofilm formers
(LBFs) or high biofilm formers (HBFs) within the spectrum have
differential clinical outcomes. The aim of this study was therefore
to investigate the impact of biofilm formation by Candida species
on the clinical outcomes of BSI in a defined Scottish cohort.Patients and methodsPatients and variables
A retrospective study of all cases of Candida BSI was carried out
within Scotland under NHS Caldicott Guardian approval from
March 2012 to February 2013. Candida BSI was reported in 217
patients from 11 different health boards; clinical data were
obtained from 157 patients. The complete datasets of patient
demographics, underlying medical conditions and details of
antimicrobial therapy were collected through a review of the
medical case notes in each health board. Where available (134
patients), patient outcomes were followed from the first posi-
tive blood culture until 30 days or death, and clinical details,
including the presence of indwelling medical devices in the 30
days prior to the detection of Candida BSI were also collected.
All data were collected and stored electronically within a
database (Excel, Microsoft).
Isolate collection
Blood cultures from 217 patients were processed according
to routine standard operating procedures in each of theClinical Microbiology and Infection © 2015 The Authors. Published by Elsevier Ltd on behalf of
This is an open access article under the CC BY license (http://creativecommons.org/licenses/by/4referring laboratories. When available, multiple isolates were
collected from some of these patients within the observation
period of 30 days. All clinical isolates obtained during this
period were independently identified by the use of Colorex
Candida chromogenic plates (E&O Laboratories, Bonny-
bridge, UK), as confirmed by matrix-assisted laser desorption
ionization time-of-flight mass spectrometry at the Public
Health England Southwest Laboratory (Bristol), and were
stored in Microbank vials (Pro-Lab Diagnostics, Brom-
borough, UK) at −80°C until further use. These isolates were
subcultured on Sabouraud’s dextrose agar (Sigma-Aldrich,
Poole, UK). Plates were incubated at 30°C for 48 h, and
maintained at 4°C.
Biofilm formation
Candida species biofilms were grown according to our estab-
lished protocols for 24 h [11], and the biomass of each isolate
was assessed with the crystal violet (CV), XTT and SYTO9
assays, as previously reported [10,12,13]; isolates were
grouped on the basis of their level of biomass distribution
(optical density (OD)570 nm values). Isolates within the first
quartile (Q1) were classed as LBFs, isolates with a biomass
greater than the third quartile (Q3) were classed as HBFs, and
those in between were classed as intermediate biofilm formers
(IBFs) (second quartile (Q2)) [10]. The susceptibilities of
C. albicans biofilm formation to different classes of antifungal
were also assessed, with 24-h biofilms being treated with either
2 mg/L or 200 mg/L voriconazole, caspofungin or amphotericin
B for 24 h. Following treatment, the proportional viability was
compared with that untreated control by use of an XTT
metabolic assay [13].
Statistical analysis
Initially, all data were numerically coded and labelled for each
variable, and analysed with SPSS software (SPSS, Chicago, IL,
USA). Categorical variables were compared between groups by
use of the two-tailed χ2 test or Fisher’s exact test, as appro-
priate. Two groups of any continuous variables were compared
by the use of Student’s t-test or the Mann–Whitney U-test, as
appropriate. Pairwise correlations between biofilm assays were
determined by calculating two-tailed Pearson correlation co-
efficients. The survival distribution function was estimated with
the Kaplan–Meier method, and a non-parametric log-rank test
was used to compare the survival curves among the different
groups. Variables showing a significant association with survival
according to Student’s t-test or the χ2 test were included in
subsequent univariate and multivariate Cox regression ana-
lyses, to generate the survival curves, hazard ratios (HRs), and
95% CIs.European Society of Clinical Microbiology and Infectious Diseases, CMI, 22, 87–93
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species
Data from the most recent (2011) census (http://www.scrol.
gov.uk/scrol/common/home.jsp) list the population of Scot-
land as 5 295 403. The population-based incidence of BSI in
Scotland can therefore be calculated as 4.1 per 100 000 pop-
ulation. Of the 280 isolates collected in this study from 217
patients, 115 were found to be C. albicans and 98 were Candida
glabrata. Of the 134 cases for which patient mortality data were
available, the overall crude mortality rate was 41%, which was
primarily associated with C. albicans (47.3%), followed by
C. glabrata (34.5%) and other species (18.2%).
Clinical parameters influencing patient mortality
Initially, we assessed the influence of different clinical variables
and underlying conditions on patient mortality (Table 1). The
results showed that patient age was significantly associated with
mortality (p 0.023). Other variables, including underlying clin-
ical conditions, i.e. diabetes, liver disease, autoimmune disor-
ders, and others, were also assessed, and found not to be
statistically associated with patient mortality. Moreover, 96.4%
of patients had lines in situ, including 93% of patients with CVCs.
Further analysis showed an association between line removal
after diagnosis of Candida BSI and mortality (p 0.032).
Relationship between biofilm formation and mortality
Biofilm formation (biomass) by different Candida species was
assessed with CV, XTT and SYTO9 assays of C. albicans (n = 107),TABLE 1. Variables stratified according to the survival or
death status at the 30-day endpoint for the 134 patients
studied
Variables % Survived % Died p
Age (years), mean ± SD 58.6 ± 20.7 (79) 66.9 ± 20.0 (55) 0.023
Male sex 48.1 (79) 83.6 (55) 0.096
Diabetes 25.6 (78) 32.7 (55) 0.437
Surgery 63.6 (22) 50.0 (18) 0.523
Radiotherapy 37.5 (16) 30.8 (13) 1
Chemotherapy 64.3 (14) 56.3 (16) 0.722
Solid organ transplant 5.1 (79) 0.0 (55) 0.144
Metastatic 61.1 (18) 85.7 (14) 0.235
Solid tumour 32.1 (78) 38.9 (54) 0.460
Autoimmune or
genetic disorder
11.4 (79) 7.4 (54) 0.559
Renal failure 32.9 (73) 42.2 (45) 0.330
Liver disease 8.3 (72) 14.3 (49) 0.374
Alcohol abuse 10.5 (76) 15.4 (52) 0.428
ICU admission 19.7 (76) 28.8 (52) 0.289
Parenteral nutrition 43.1 (72) 37.3 (51) 0.579
Line removed 82.2 (45) 55.0 (20) 0.032
Antifungals in previous
3 months
27.5 (69) 14.0 (50) 0.115
Values in parentheses indicate the total no. of patients assessed for each variable.
Bold type indicates a significant result.
ICU, intensive care unit; SD, standard deviation.
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(n = 10). When the different biomass assays were compared,
significant positive correlations were found for C. albicans be-
tween CV and XTT (r = 0.8), between CV and SYTO9 (r = 0.6),
and between XTT and SYTO9 (r = 0.4) (Fig. S1). On the basis of
this, CV was used for further categorization of the isolates. Fig. 1
shows that biofilm formation by different Candida species was
heterogeneous, irrespective of the species tested. Isolates were
categorized as LBFs or HBFs if their CV absorbance was less than
Q1 (OD570 nm = 0.15) or greater than Q3 (OD570 nm = 0.3),
respectively. Those isolates betweenQ1 andQ3were defined as
IBFs. C. albicans, C. parapsilosis and C. tropicalis were found to be
HBFs (n = 35, n = 16, and n = 5, respectively), IBFs (n = 36, n = 3,
and n = 5, respectively), or LBFs (n = 35 n = 13, and n = 0,
respectively), whereas C. glabrata organisms were found to be
only LBFs (n = 98).
Given the significant disparity in biofilm formation between
C. albicans and C. glabrata (p <0.0001), we analysed patient
mortality (n = 95) with respect to these two groups on the
basis of 30-day survival from the first positive blood culture
(Fig. 2). Comparison of these by the use of Cox regression
analysis adjusted for age showed a trend for higher mortality
with C. albicans than with C. glabrata (p 0.260) (Fig. 2a), and,
after adjustment for catheter line removal from patients
(n = 42), showed a significant difference between these curvesFIG. 1. Biofilm formation by Candida species. Candida bloodstream
isolates were evaluated for biofilm formationwith standardizedmethods.
Candida isolates standardized (1 × 106 cells/mL) in RPMI-1640 were
grown in flat-bottomed 96-wellmicrotitre plates for 24 h at 37°C.Mature
biofilms were carefully washed with phosphate-buffered saline and
allowed to air dry, and biomass quantified by staining with 0.05% w/v
crystal violet solution. The biofilms were washed and destained with
100% ethanol. Biomass was quantified spectrophotometrically by reading
the optical density (OD) at 570 nm in a microtitre plate reader (FluoStar
Omega BMG Labtech, Aylesbury, UK). Six replicates were used for each
isolate, and the mean of each is represented. ***p <0.0001.
alf of European Society of Clinical Microbiology and Infectious Diseases, CMI, 22, 87–93
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FIG. 2. Survival of patients with Candida albicans and Candida glabrata
infection. Survival of patients infected with C. albicans (solid line) and
C. glabrata (dotted line) was monitored over a period of 30 days from
the first Candida-positive blood culture. Cox regression plots, adjusted
only for patient age (n = 95) (a) or for age and catheter removal (n = 42)
(b), in patients with C. albicans and C. glabrata infection are shown.
Comparison between these curves showed a statistically significant
difference in the mortality rate in (b) (p <0.05).
FIG. 3. Survival of patients with Candida albicans high biofilm formers
(HBFs) and low biofilm formers (LBFs). Survival of patients infected
with C. albicans HBFs (n = 17) and LBFs (n = 17) was monitored over a
period of 30 days from the first Candida-positive blood culture. Cox
regression plots adjusted for (a) age only (n = 34) or (b) age and
parenteral nutrition (n = 28) in patients with C. albicans HBFs (solid line)
and LBFs (dotted line) are shown. Comparison between these
curves showed a statistically significant difference in the mortality rate
in (b) (p <0.05).
90 Clinical Microbiology and Infection, Volume 22 Number 1, January 2016 CMI(Fig. 2b; p 0.048, HR 3.4, 95% CI 0.99–11.47). Next, we
investigated whether the levels of biofilm formation by
C. albicans showed an association with mortality, by specifically
evaluating isolates defined as LBFs (n = 17) and HBFs (n = 17).Clinical Microbiology and Infection © 2015 The Authors. Published by Elsevier Ltd on behalf of
This is an open access article under the CC BY license (http://creativecommons.org/licenses/by/4The Cox regression plots adjusted for age showed a trend for a
higher mortality rate with HBFs than with LBFs (p 0.192)
(Fig. 3a). A previous study has shown that administration of
parenteral nutrition induces C. albicans germination and biofilmEuropean Society of Clinical Microbiology and Infectious Diseases, CMI, 22, 87–93
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ments for administration of parenteral nutrition, and these
revealed a significant difference in survival between the LBF and
HBF groups (Fig. 3b; p 0.024, HR 5.99, 95% CI 1.3–28.3).
Biofilm sensitivity to antifungals
On the basis of these data, and given the positive correlations
between biofilm formation and mortality, we tested C. albicans
LBFs (n = 10) and HBFs (n = 10) for their response to azoles
(voriconazole), polyenes (amphotericin B) and echinocandins
(caspofungin) at low (2 mg/L) and high (200 mg/L) concentra-
tions. Although both 2 mg/L and 200 mg/L voriconazole were
equally ineffective against mature HBF and LBF biofilms
(Fig. 4a,b), a significant difference in overall activity was
observed between HBFs and LBFs at both 2 mg/L (p <0.05) and
200 mg/L (p <0.001). Conversely, caspofungin and amphoter-
icin B were effective against both HBFs and LBFs, although the
levels of biofilm formation significantly impacted on caspofungin
sensitivity (2 mg/L, p <0.05; 200 mg/L, p <0.001). Furthermore,
a paradoxical effect was found for caspofungin with HBFs,
whereby 200 mg/L was significantly less effective than 2 mg/L (p
<0.05). Conversely, no such effect was found in LBFs.
Amphotericin B was shown to be equally effective against LBFs
and HBFs, although a significant difference was found between
2 mg/L and 200 mg/L (HBFs, p <0.0005; LBFs, p <0.005).FIG. 4. Impact of Candida albicans biofilm formation on antifungalDiscussion
susceptibility. Ten low biofilm formers (LBFs) and high biofilm formers
(HBFs) were standardized to 1 × 106 cells/mL in RPMI-1640, and grown
as biofilms in flat-bottomed 96-well microtitre plates for 24 h. Biofilms
were washed with phosphate-buffered saline before being treated with
2 mg/L (a) or 200 mg/L (b) voriconazole (VRZ), caspofungin (CAS), and
amphotericin B (AMB). After incubation for 24 h, metabolic activity was
measured with the XTT assay, with optical density being read at
492 nm. Percentage viability was calculated relative to untreated
controls, and data are presented as mean ± standard deviation. Eight
replicates were used for each isolate, and repeated on two separate
occasions. *p <0.05, ***p <0.001.A retrospective analysis of patients with Candida BSI in Scotland
was performed to determine the risk factors associated with
mortality in the defined patient cohort. We report an adverse
influence of biofilm formation by Candida species on the clinical
outcomes of patients with C. albicans BSI.
The incidence of Candida BSI from this study in 2012–2013
(4.1 cases per 100 000 population per year) is comparable to
that in 2005–2006 (4.8 cases per 100 000 population per year)
[15]. The difference could be explained by an increasing pop-
ulation and by inaccurate reporting of the cases, and is there-
fore likely to represent a minimum estimate of the incidence of
Candida BSI in Scotland. Our previous study reported that
C. albicans was most prevalent within the population (50%),
followed by C. glabrata (21%) [15]. The data from this study
demonstrate a changing epidemiology, with a notable decrease
in the incidence of C. albicans (41%) and a concurrent increase
in the incidence of C. glabrata (35%). The reason for this is
uncertain, but the overuse of azoles may have inadvertently
selected C. glabrata, which has reduced sensitivity to
fluconazole. The use of matrix-assisted laser desorption ioni-
zation time-of-flight mass spectrometry in addition to standardClinical Microbiology and Infection © 2015 The Authors. Published by Elsevier Ltd on beh
This is an olaboratory identification may have improved the isolation rate
of this organism [16–18].
Among the patients with a BSI, we found a mortality rate of
41%, for which a number of risk factors were identified. Risk
factors such as neutropenia, glucocorticosteroids, parenteral
nutrition and CVC use were reported to be associated with
Candida BSI [19]. In addition to Candida infection, the patient
age covariate had a significant influence on patient mortality. It
is of significance, however, that our data show that removal of
catheter lines after diagnosis of candidaemia significantlyalf of European Society of Clinical Microbiology and Infectious Diseases, CMI, 22, 87–93
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the current guidelines for the management of catheter-
associated infection and their clinical management; that is,
where possible, the catheter should be removed in non-
neutropenic patients [7,20,21]. In a prospective randomized
trial, it was shown that the removal of a catheter within the first
24 h of candidaemia resulted in a shorter duration of candi-
daemia [22]. Furthermore, a recent meta-analysis reported that
removal of the CVC is associated with decreased mortality [6].
Biofilms are relatively refractory to antifungal therapy [3,11];
therefore, unsurprisingly, inadequate antifungal therapy (OR
2.35, p 0.03) and biofilm formation (OR 2.33, p 0.007) were
reported to be independent predictors of mortality in candi-
daemia patients [8]. Biofilm formation by clinical isolates of
different Candida species was found to be highly variable,
particularly between C. albicans and C. glabrata. Survival analysis
was carried out to investigate the impact of their biofilm for-
mation on clinical outcome, with Cox regression showing a
trend for C. albicans to be more associated with mortality (p
0.026). After adjustment for the removal of lines, a significant
difference in mortality was observed (p <0.05). These data are
different from those previously reported, where no significant
differences in survival between patients with C. glabrata and
with C. albicans BSI was observed [23]. In addition, Cox
regression analysis with the C. albicans HBF (41.2% mortality)
and LBF (35.2% mortality) groups adjusted for patient age
showed a trend for a lower survival rate with HBFs than with
LBFs, which is in accordance with a previous study showing
51.2% mortality in the biofilm-forming group, as compared with
31.7% in the non-biofilm-forming group (p 0.004) [9]. Paren-
teral nutrition, including lipid emulsion, has been shown to
induce C. albicans germination and increase biofilm formation in
indwelling catheters [14]. Therefore, Cox regression analysis
with adjustment for parenteral nutrition was performed, and
revealed a significant impact on biofilm-related mortality.
However, a caveat to the interpretation of these data is the low
sample numbers, owing to the availability of complete datasets.
Given that biofilm formation by clinical isolates is heteroge-
neous and has an impact on patient mortality, we tested their
antifungal sensitivity to determine whether it was affected. Bio-
films were treated with antifungals at a clinically relevant con-
centration of 2 mg/L and another concentration that is
potentially useful in antifungal lock therapy (200 mg/L) [24]. Our
data illustrate a significant difference between HBFs and LBFs in
sensitivity to voriconazole and caspofungin. However, ampho-
tericin B is equally effective against both groups. Whereas the
clinical data show that azoles were used extensively to treat
82.2% of patients in this study, our data show that this class of
antifungal is less effective against matured biofilms. When echi-
nocandins were compared with polyenes, the removal of theClinical Microbiology and Infection © 2015 The Authors. Published by Elsevier Ltd on behalf of
This is an open access article under the CC BY license (http://creativecommons.org/licenses/by/4catheter showed no improved time to mycological eradication,
possibly because of the effectiveness of both antifungal agents
against biofilms [25]. Furthermore, with HBFs, we found a par-
adoxical effect of lower percentage kill with a higher concen-
tration of caspofungin (200 mg/mL) than with 2 mg/L, in vitro
(Fig. 4b). The exact mechanism causing this paradoxical effect
with HBFs and its clinical relevance are unknown.
In summary, C. albicans remains a predominant Candida spe-
cies associated with high mortality in candidaemia patients, and,
within this species, biofilm heterogeneity has a direct impact on
patient survival, and potentially on antifungal sensitivities, based
on in vitro studies. These findings highlight the importance of
biofilm stratification in the clinical management of candidaemia
cases, to determine whether they should be managed with
azoles or other fungicidal classes of antifungal agent. Moreover,
understanding the genetic basis of these isolates will enable us to
devise and develop a biomarker for biofilm-related Candida BSI,
and to create more appropriate antifungal therapies, which,
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